18F-ICMT-11, a Caspase-3–Specific PET Tracer for Apoptosis: Biodistribution and Radiation Dosimetry
Amarnath Challapalli,Laura M. Kenny,William A. Hallett,Kasia Kozlowski,Giampaolo Tomasi,Mihir Gudi,Adil Al-Nahhas,R. Charles Coombes,Eric O. Aboagye +8 more
Reads0
Chats0
TLDR
Injection of 18F-ICMT-11 was well tolerated in all subjects, with no serious tracer-related adverse events reported, and the dosimetry profile comparable to other common 18F PET tracers is supported.Abstract:
Effective anticancer therapy induces tumor cell death through apoptosis. Noninvasive monitoring of apoptosis during therapy may provide predictive outcome information and help tailor treatment. A caspase-3–specific imaging radiotracer, 18F-(S)-1-((1-(2-fluoroethyl)-1H-[1,2,3]-triazol-4-yl)methyl)-5-(2(2,4-difluorophenoxymethyl)-pyrrolidine-1-sulfonyl)isatin (18F-ICMT-11), has been developed for use in PET studies. We report the safety, biodistribution, and internal radiation dosimetry profiles of 18F-ICMT-11 in 8 healthy human volunteers. Methods:18F-ICMT-11 was intravenously administered as a bolus injection (mean ± SD, 159 ± 2.75 MBq; range, 154–161 MBq) to 8 healthy volunteers (4 men, 4 women). Whole-body (vertex to mid thigh) PET/CT scans were acquired at 6 time points, up to 4 h after tracer injection. Serial whole blood, plasma, and urine samples were collected for radioactivity measurement and radiotracer stability. In vivo 18F activities were determined from quantitative analysis of the images, and time–activity curves were generated. The total numbers of disintegrations in each organ normalized to injected activity (residence times) were calculated as the area under the curve of the time–activity curve, normalized to injected activities and standard values of organ volumes. Dosimetry calculations were then performed using OLINDA/EXM 1.1. Results: Injection of 18F-ICMT-11 was well tolerated in all subjects, with no serious tracer-related adverse events reported. The mean effective dose averaged over both men and women was estimated to be 0.025 ± 0.004 mSv/MBq (men, 0.022 ± 0.004 mSv/MBq; women, 0.027 ± 0.004 mSv/MBq). The 5 organs receiving the highest absorbed dose (mGy/MBq), averaged over both men and women, were the gallbladder wall (0.59 ± 0.44), small intestine (0.12 ± 0.05), upper large intestinal wall (0.08 ± 0.07), urinary bladder wall (0.08 ± 0.02), and liver (0.07 ± 0.01). Elimination was both renal and via the hepatobiliary system. Conclusion:18F-ICMT-11 is a safe PET tracer with a dosimetry profile comparable to other common 18F PET tracers. These data support the further development of 18F-ICMT-11 for clinical imaging of apoptosis.read more
Citations
More filters
Journal ArticleDOI
PET/CT imaging in cancer: current applications and future directions.
TL;DR: Emerging methods for PET imaging of other biologic processes relevant to cancer are reviewed, including cellular proliferation, tumor hypoxia, apoptosis, amino acid and cell membrane metabolism, and imaging of tumor receptors and other tumor‐specific gene products.
Journal ArticleDOI
Imaging cell death.
André A. Neves,Kevin M. Brindle +1 more
TL;DR: This work focuses here on cell death imaging probes, which either have been trialed in the clinic or have significant promise, based on preclinical studies, and develops and validate imaging biomarkers for these hallmarks.
Journal ArticleDOI
In Vivo Imaging of Human Neuroinflammation.
TL;DR: This Review provides an overview of state-of-the-art techniques for imaging human neuroinflammation which have potential to impact patient care in the foreseeable future.
Journal ArticleDOI
Caspase-responsive smart gadolinium-based contrast agent for magnetic resonance imaging of drug-induced apoptosis
Deju Ye,Adam J. Shuhendler,Prachi Pandit,Kimberly D. Brewer,Sui Seng Tee,Lina Cui,Grigory Tikhomirov,Brian K. Rutt,Jianghong Rao +8 more
TL;DR: It is demonstrated that C-SNAM reports caspase-3/7 activity by generating a significantly brighter T1-weighted MR signal compared to non-treated tumors following intravenous administration of C- SNAM, providing great potential for high-resolution imaging of tumor apoptosis in vivo.
Journal ArticleDOI
Molecular imaging of apoptosis: from micro to macro.
TL;DR: In this paper, the authors mainly discuss microscopic imaging assays and macroscopic imaging probes, ranging in complexity from simple attachments of reporter moieties to proteins that interact with apoptotic biomarkers, to rationally designed probes that target biochemical changes.
References
More filters
Journal ArticleDOI
The hallmarks of cancer.
TL;DR: This work has been supported by the Department of the Army and the National Institutes of Health, and the author acknowledges the support and encouragement of the National Cancer Institute.
Journal ArticleDOI
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Elizabeth Eisenhauer,P. Therasse,Jan Bogaerts,Lawrence H. Schwartz,Daniel J. Sargent,Robert Ford,Janet Dancey,S. Arbuck,S. Gwyther,Margaret M. Mooney,Larry Rubinstein,Lalitha K. Shankar,Lori E. Dodd,Robert M. Kaplan,Denis Lacombe,Jaap Verweij +15 more
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Book
The 2007 recommendations of the International Commission on Radiological Protection
TL;DR: These revised Recommendations for a System of Radiological Protection formally replace the Commission's previous, 1990, Recommendations; and update, consolidate, and develop the additional guidance on the control of exposure from radiation sources issued since 1990.
Journal ArticleDOI
Emerging roles of caspase-3 in apoptosis
Alan G. Porter,Reiner U. Jänicke +1 more
TL;DR: Caspase-3 is essential for certain processes associated with the dismantling of the cell and the formation of apoptotic bodies, but it may also function before or at the stage when commitment to loss of cell viability is made.